Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
The independent financial analyst theScreener just lowered the general evaluation of SUMITOMO DAINIPPON PHA. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 1, 2022, the closing price was...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Summary Marketline's Nanocarrier Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Nanocarrier Co., Ltd. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the o...
EM Pullback Opportunity Supporting our global bull market thesis, uptrends remain intact for the major global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM). At this point, concerns surrounding the Wuhan coronavirus have led to some market setbacks and deterioration in market indicators, however they have not resulted in breakdowns. This is true even for areas of the market most-directly affected, including China (MSCI China) and emerging markets (MSCI EM). For these reasons and, as long as ther...
Int'l Equity Strategy In using technical analysis, we let the market be our guide. That is, we analyze what is true in the market, utilizing the vast array of tools in our technical analysis toolbox which we then formulate into our outlook using a weight of the evidence approach. In a world where there are no shortages of things to worry about (trade wars, central banks, Trump impeachment, negative interest rates, low global growth, Brexit, Manufacturing weakness, elections, Hong Kong protests,...
The PSA Japan Research Round-Up for the week ending February 16, 2018 Contents at a Glanceï¶ The Weekly Comment by Pelham Smithers: Surf’s up: Pelham Smithers considers whether we are starting to see a break in the link between the yen and the Japanese stock market.ï¶ Reports / Flash Notes Summaries 1. Mitsubishi Electric (6503 JP): FA and Infrastructure Upturn 2. Sony (6758 JP): FY17 Outlook and SoTP5ï¶ Company / Sector / Thematic Comments 1. Sony (6758 JP) Surprises, Irritates with Peter Ra...
PSA Today Feb 15: Japan Market Comment by Pelham Smithers, Joel Scheiman and Thao Nguyen Nikkei ¥21,464.98 (+¥310.81/ +1.47%); Topix ¥1,719.27 (+¥16.55/ +0.97%); ¥/$106.56Tags: Remixpoint (3825 JP), SBI Holdings (8473 JP), mixi (2121 JP), Kirin (2503 JP), Sony (6758 JP), Facebook (FB US), Apple (AAPL US), Netflix (NFLX US), Capcom (9697 JP), Bandai Namco (7832 JP), Sumitomo Dainippon Pharma (4506 JP), Nitto Denko (6988 JP), Tokyo Ohka Kogyo (4186 JP), Nissha (7915 JP), Showa Denko (SDK, 4004 JP)...
PSA is structurally negative on the outlook for the pharmaceutical industry, and cyclically negative on the sector from an investment strategy viewpoint. For a stock to look attractive in the current environment, it either needs to be cheap, with positive earnings momentum (e.g. Astellas (4503)), or to be in a strong position to change its fortunes for the better (e.g. Chugai (4519), or Sosei (4565)). On 14.2x FY16e EV/OP, Sumitomo Dainippon Pharmaceutical (SDP) appears fully priced two years a...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.